Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10013889HBVENSG00000012124.17protein_codingCD22NoNo933P20273
Q0EAF5
TVIS30082490HIVENSG00000012124.17protein_codingCD22NoNo933P20273
Q0EAF5
TVIS20009984HPVENSG00000012124.17protein_codingCD22NoNo933P20273
Q0EAF5
TVIS20068354HPVENSG00000012124.17protein_codingCD22NoNo933P20273
Q0EAF5
TVIS20016744HPVENSG00000012124.17protein_codingCD22NoNo933P20273
Q0EAF5
TVIS44018189HTLV-1ENSG00000012124.17protein_codingCD22NoNo933P20273
Q0EAF5
TVIS44033835HTLV-1ENSG00000012124.17protein_codingCD22NoNo933P20273
Q0EAF5
TCGA Plot Options
Drug Information
GeneCD22
DrugBank IDDB05889
Drug NameInotuzumab ozogamicin
Target IDBE0000183
UniProt IDP20273
Regulation Typeantibody
PubMed IDs28152223; 33807678
CitationsThota S, Advani A: Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017 May;98(5):425-434. doi: 10.1111/ejh.12862. Epub 2017 Mar 9.@@Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A: Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J Fungi (Basel). 2021 Mar 5;7(3). pii: jof7030186. doi: 10.3390/jof7030186.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL